Benzinga | Aug 19, 2020 11:55AM EDT

Aegis Capital Maintains Buy on VolitionRX, Lowers Price Target to $8

Aegis Capital analyst Nathan Weinstein maintains VolitionRX (AMEX:VNRX) with a Buy and lowers the price target from $10 to $8.